Compare VPG & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | SPTX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2010 | 2026 |
| Metric | VPG | SPTX |
|---|---|---|
| Price | $103.75 | $21.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $53.50 | N/A |
| AVG Volume (30 Days) | ★ 464.2K | 124.7K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,202,000.00 | N/A |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $25.58 | $17.59 |
| 52 Week High | $151.78 | $22.98 |
| Indicator | VPG | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 58.35 |
| Support Level | $93.34 | $18.47 |
| Resistance Level | $150.08 | $22.12 |
| Average True Range (ATR) | 7.38 | 1.76 |
| MACD | -1.16 | 0.04 |
| Stochastic Oscillator | 38.92 | 74.03 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.